公开(公告)号：US20230348456A1

公开(公告)日：2023-11-02

申请号：US18140302

申请日：2023-04-27

Applicant: Repare Therapeutics Inc.

Inventor： Janek SZYCHOWSKI ,  Bingcan LIU ,  Evelyne DIETRICH ,  Alexander PERRYMAN ,  Sheldon N. CRANE ,  Vouy Linh TRUONG ,  Abbas ABDOLI ,  Alexanne BOUCHARD

IPC: C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/107 ,  C07D209/46 ,  C07D493/08 ,  C07D411/14

CPC classification number: C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/107 ,  C07D209/46 ,  C07D493/08 ,  C07D411/14

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

公开(公告)号：US20230158022A1

公开(公告)日：2023-05-25

申请号：US17916773

申请日：2021-04-01

Applicant: Repare Therapeutics Inc. ,  Sinai Health System

Inventor： Daniel DUROCHER ,  Jordan YOUNG ,  Frank SICHERI ,  Janek SZYCHOWSKI ,  Bingcan LIU ,  Evelyne DIETRICH ,  Frédéric VALLÉE ,  Alexander PERRYMAN ,  Jean-François TRUCHON ,  Robert PAPP ,  Theresa ZHANG ,  Artur VELOSO ,  Jimmy FOURTOUNIS ,  Patrick BEAULIEU

IPC: A61K31/4985 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/506 ,  A61K31/541 ,  A61K31/55 ,  A61K31/501 ,  A61P35/00 ,  A61K31/444

CPC classification number: A61K31/4985 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/506 ,  A61K31/541 ,  A61K31/55 ,  A61K31/501 ,  A61P35/00 ,  A61K31/444

Abstract: Disclosed are methods of using inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1), e.g., in the treatment of subjects in need thereof.

公开(公告)号：US20230151014A1

公开(公告)日：2023-05-18

申请号：US17916760

申请日：2021-04-01

Applicant: Repare Therapeutics Inc.

Inventor： Janek SZYCHOWSKI ,  Bingcan LIU ,  Evelyne DIETRICH ,  Frédéric VALLÉE ,  Alexander PERRYMAN ,  Jean-François TRUCHON ,  Robert PAPP ,  Patrick BEAULIEU

IPC: C07D487/04 ,  C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00 ,  A61P35/00 ,  C07B2200/05

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

公开(公告)号：US20250026748A1

公开(公告)日：2025-01-23

申请号：US18696850

申请日：2022-09-29

Applicant: Repare Therapeutics Inc.

Inventor： Bingcan LIU ,  Alexander PERRYMAN ,  Philippe MOCHIRIAN ,  Michel GALLANT ,  David BENDAHAN ,  Simon SURPRENANT ,  Janek SZYCHOWSKI ,  Evelyne DIETRICH ,  Boubacar SOW ,  Monica BUBENIK

IPC: C07D417/14 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/551 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107

Abstract: Disclosed are compounds of formula (I), wherein V is N or CR; W is optionally substituted alkylene, alkenylene, alkynylene, cycloalkylene, or arylene; X is optionally substituted heterocyclylene, heteroarylene, arylene, wherein X may be substituted with -L1-Rx, wherein L1 is —O—, —NRX1—, optionally substituted heterocyclylene, heteroarylene, or cycloalkylene, Rx is optionally substituted alkyl, heteroalkyl, heterocyclyl, heteroaryl, cycloalkyl C1-6 alkyl, or heteroaryl C1-6alkyl, and RX1 is hydrogen or optionally substituted alkyl; Y is optionally substituted heterocyclyl, heteroaryl, or aryl; Z is a H, optionally substituted alkyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, heteroaryl, or aryl; and R is hydrogen, halogen, optionally substituted alkyl, CN, cycloalkyl, alkoxy, cycloalkoxy, N(R1)2, or C(O)NHz, wherein each R1 is hydrogen alkyl, or cycloalkyl. The compounds of formula (I) are useful for inhibiting human Polymerase Theta (Polθ) and for treating cancers, such as carcinoma, sarcoma, adenocarcinoma, leukemia, lymphoma, and melanoma.

公开(公告)号：US20230122909A1

公开(公告)日：2023-04-20

申请号：US17937977

申请日：2022-10-04

Applicant: Repare Therapeutics Inc.

Inventor： Janek SZYCHOWSKI ,  Bingcan LIU ,  Evelyne DIETRICH ,  Frédéric VALLÉE ,  Alexander PERRYMAN ,  Jean-François TRUCHON ,  Robert PAPP ,  Patrick BEAULIEU ,  Vouy Linh TRUONG ,  Kaveh MATINKHOO ,  Sheldon N. CRANE

IPC: C07D487/04 ,  C07D471/04 ,  C07D209/12

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.